Kidney cancer
1L advanced ccRCC*,1
Kidney cancer
1L advanced ccRCC*,1
*Nivolumab in combination with ipilimumab is only approved for 1L ccRCC patients with an intermediate or poor risk profile.
1L, first-line; ccRCC, clear cell renal cell carcinoma; IV, intravenous; QxW, every x weeks.
1. Opdivo® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb; 2023.